Management of ocular stem cell disease.
Management of ocular stem cell disease.
复制标题
DOI:
10.1097/iio.0b013e3181e20d64
复制
发表时间:
2010-01-01
影响因子:
--
通讯作者:
Neff, Kristiana D
中科院分区:
文献类型:
--
作者:
Biber, Joseph M;Holland, Edward J;Neff, Kristiana D
Regeneration of the corneal epithelium occurs on average every 7 days. The source of renewal for these cells is a stem cell population located at the basal layer of the epithelium at the corneoscleral junction. This anatomic site is referred to as the limbus. Our understanding of the limbus and its collection of stem cells is continuing to evolve, as is our approach to ocular surface failure in patients with stem cell dysfunction. Limbal stem cell deficiency can be caused by multiple disease processes including aniridia, Stevens Johnson Syndrome (SJS), ocular cicatricial pemphigoid (OCP), and chemical/thermal/mechanical injuries. Clinically, it presents with loss of the palisades of Vogt, conjunctivalization of the corneal surface, and a persistent epithelial defect. Histologically, the hallmark of limbal stem cell deficiency is the presence of conjunctival goblet cells in the corneal epithelium. The purpose of this paper is to explain our approach to patients with ocular surface disease. Management decisions about these challenging patients are dependent on the severity and staging of the disease. There are multiple approaches to the surgical management of these patients and the postoperative course can often be filled with unique challenges as well. Often, the ultimate goal of ocular surface reconstruction is to provide an adequate environment for an optical keratoplasty to be successful and restore a patient’s vision in the long term. www. internat-ophthalmology. com| 25